Annual dementia incidence and monetary burden attributable to fine particulate matter (PM2.5) exposure in Sweden

被引:9
作者
Kriit, Hedi Katre [1 ]
Forsberg, Bertil [1 ]
Astrom, Daniel Oudin [1 ]
Oudin, Anna [1 ,2 ]
机构
[1] Umea Univ, Sect Sustainable Hlth, Dept Publ Hlth & Clin Med, Umea, Sweden
[2] Lund Univ, Tornblad Inst, Div Occupat & Environm Med, Dept Lab Med, Biskopsgatan 7,223v62, Lund, Sweden
关键词
Dementia; Incidence; Particulate matter; Air pollution; PM2; 5; Societal costs; QALY; AIR-POLLUTION; POPULATION; ALZHEIMERS; MORTALITY; DISEASE; COHORT; IMPACT; OZONE; LIFE;
D O I
10.1186/s12940-021-00750-x
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Background Alzheimer's disease (AD) and other dementias currently represent the fifth most common cause of death in the world, according to the World Health Organization, with a projected future increase as the proportion of the elderly in the population is growing. Air pollution has emerged as a plausible risk factor for AD, but studies estimating dementia cases attributable to exposure to fine particulate matter (PM2.5) air pollution and resulting monetary estimates are lacking. Methods We used data on average population-weighted exposure to ambient PM2.5 for the entire population of Sweden above 30 years of age. To estimate the annual number of dementia cases attributable to air pollution in the Swedish population above 60 years of age, we used the latest concentration response functions (CRF) between PM2.5 exposure and dementia incidence, based on ten longitudinal cohort studies, for the population above 60 years of age. To estimate the monetary burden of attributable cases, we calculated total costs related to dementia, including direct and indirect lifetime costs and intangible costs by including quality-adjusted life years (QALYs) lost. Two different monetary valuations of QALYs in Sweden were used to estimate the monetary value of reduced quality-of-life from two different payer perspectives. Results The annual number of dementia cases attributable to PM2.5 exposure was estimated to be 820, which represents 5% of the annual dementia cases in Sweden. Direct and indirect lifetime average cost per dementia case was estimated to correspond euro 213,000. A reduction of PM2.5 by 1 mu g/m(3) was estimated to yield 101 fewer cases of dementia incidences annually, resulting in an estimated monetary benefit ranging up to 0.01% of the Swedish GDP in 2019. Conclusion This study estimated that 5% of annual dementia cases could be attributed to PM2.5 exposure, and that the resulting monetary burden is substantial. These findings suggest the need to consider airborne toxic pollutants associated with dementia incidence in public health policy decisions.
引用
收藏
页数:12
相关论文
共 55 条
  • [31] Societal costs of air pollution-related health hazards: A review of methods and results
    Pervin T.
    Gerdtham U.-G.
    Lyttkens C.H.
    [J]. Cost Effectiveness and Resource Allocation, 6 (1)
  • [32] Air Pollution and Dementia: A Systematic Review
    Peters, Ruth
    Ee, Nicole
    Peters, Jean
    Booth, Andrew
    Mudway, Ian
    Anstey, Kaarin J.
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2019, 70 : S145 - S163
  • [33] Estimating the costs of air pollution to the National Health Service and social care: An assessment and forecast up to 2035
    Pimpin, Laura
    Retat, Lise
    Fecht, Daniela
    de Preux, Laure
    Sassi, Franco
    Gulliver, John
    Belloni, Annalisa
    Ferguson, Brian
    Corbould, Emily
    Jaccard, Abbygail
    Webber, Laura
    [J]. PLOS MEDICINE, 2018, 15 (07):
  • [34] Prince M., 2016, World Alzheimer Report 2016: Improving Healthcare for People Living with Dementia: Coverage, Quality and Costs Now and in the Future
  • [35] The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature
    Ryen, Linda
    Svensson, Mikael
    [J]. HEALTH ECONOMICS, 2015, 24 (10) : 1289 - 1301
  • [36] Schmitt L, 2015, COST EFFECTIVNESS AI
  • [37] Silva Maren de Moraes e, 2018, Dement. neuropsychol., V12, P123
  • [38] Socialstyrelsen, 2011, NAT RIKTL FOR SJUKD
  • [39] Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness
    Svensson, Mikael
    Nilsson, Fredrik O. L.
    Arnberg, Karl
    [J]. PHARMACOECONOMICS, 2015, 33 (11) : 1229 - 1236
  • [40] Svensson T., 2019, UNDERLAG REVIDERADE